DaVita Inc.
DVA Healthcare Medical - Care Facilities NYSE
$107.56
$-0.56 (-0.52%)
Open: $108.40 | High: $108.54 | Low: $106.70 | Prev Close: $108.12
Market Cap: $7.59B
Volume: 182K | Avg: 951K
Last updated: January 26, 2026 at 06:02 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 485
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 11.10 |
| P/B Ratio | -13.55 |
| P/S Ratio | 0.57 |
| EPS | $9.69 |
| Beta | 0.99 |
| Shares Outstanding | 70.60M |
| 52-Week High | $179.60 |
| 52-Week Low | $101.00 |
| SMA 50 | $115.28 |
| SMA 200 | $131.16 |
| Next Earnings | February 02, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 32.0% |
| Operating Margin | 15.4% |
| Net Margin | 5.8% |
| ROE | -283.9% |
| ROA | 4.4% |
| Debt/Equity | -26.02 |
| Current Ratio | 1.36 |
| Quick Ratio | 1.32 |
Balance Sheet
| Total Assets | $17.29B |
| Total Liabilities | $15.19B |
| Total Equity | $121.12M |
|
|
|
| Cash | $794.93M |
| Total Debt | $12.07B |
| Net Debt | $11.27B |
Income Statement
| Revenue | $12.82B |
| Gross Profit | $4.22B |
| Operating Income | $2.09B |
| Net Income | $936.34M |
|
|
|
| EBITDA | $2.72B |
| Revenue/Share | $184.78 |
Cash Flow
| Operating CF | $2.02B |
| CapEx | $555.44M |
| Free Cash Flow | $1.47B |
|
|
|
| Book Value/Share | $21.20 |
| Tangible Book/Share | $-86.51 |
| Equity/Share | $-7.93 |
Technical Indicators
| RSI (14) | 50.00 Neutral |
| MACD |
0.00
Signal: 0.00
|
| Volatility | 0.00% |
| Trading Signal | Neutral |
Performance & Returns
Insufficient historical data
Insufficient historical data (need 200+ days, have 0)Sector Comparison (Healthcare)
| Metric | DVA | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 11.1 | 35.85 | 11% |
| P/B Ratio | -13.55 | 0.57 | 7% |
| ROE (%) | -283.93% | 20.80% | 2% |
| Net Margin (%) | 5.80% | 9.74% | 26% |
| Stock Score | 485 | 468.0 | 48% |
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DVA | $107.56 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | 50.00 | 0.00 | 0.00% | 0 | Neutral | Mixed |
Candlestick Patterns
There wasn't any recognizable pattern for the DVA stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| DVA | DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know | Neutral | zacks.com | Read More |
| DVA | DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call | Neutral | prnewswire.com | Read More |
| DVA | Here's Why You Should Hold DaVita Stock in Your Portfolio for Now | Neutral | zacks.com | Read More |
| DVA | DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights | Negative | zacks.com | Read More |
| DVA | Why DaVita HealthCare (DVA) Dipped More Than Broader Market Today | Neutral | zacks.com | Read More |
Recent Insider Trading
No recent insider trading data available for DVA
Company Information
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
| CEO | Javier J. Rodriguez |
| Employees | 76000 |
| Country | US |
| IPO Date | 1995-10-31 |
| Exchange | NYSE |
| Website | https://www.davita.com |
| Sector | Healthcare |
| Industry | Medical - Care Facilities |
Similar Stocks (Healthcare - Medical - Care Facilities)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category